Isis, Biogen move forward on $300M antisense pact

Isis ($ISIS) and partner Biogen Idec ($BIIB) have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $300 million alliance to advance antisense treatments. Isis is due about $9.3 million in milestone payments tied to the first dosing in a study on children with SMA and the extension of another on infants. The initial deal, signed in 2012, gave Isis an upfront payment of $29 million with $45 million tied to development milestones and up to $225 million down the line. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.